These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 18692932)
1. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Yamana A; Arita M; Furuta M; Shimajiri Y; Sanke T Diabetes Res Clin Pract; 2008 Oct; 82(1):127-31. PubMed ID: 18692932 [TBL] [Abstract][Full Text] [Related]
2. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Mori Y; Itoh Y; Tajima N Adv Ther; 2007; 24(1):146-53. PubMed ID: 17526471 [TBL] [Abstract][Full Text] [Related]
3. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049 [TBL] [Abstract][Full Text] [Related]
4. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143 [TBL] [Abstract][Full Text] [Related]
5. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472 [TBL] [Abstract][Full Text] [Related]
6. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. Suksomboon N; Poolsup N; Prasit T J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583 [TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Bahadir O; Uzunlulu M; Oguz A; Bahadir MA Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371 [TBL] [Abstract][Full Text] [Related]
8. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes. Kobayashi K; Ohno Y; Takenaka T; Ikeda N; Okada H; Kanno Y; Suzuki H Clin Exp Hypertens; 2011; 33(2):100-5. PubMed ID: 21269058 [TBL] [Abstract][Full Text] [Related]
9. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S; Takeuchi M Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852 [TBL] [Abstract][Full Text] [Related]
10. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784 [TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient. Ucciferri C; Mancino P; Vecchiet J; Falasca K Int J Immunopathol Pharmacol; 2009; 22(3):853-7. PubMed ID: 19822103 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430 [TBL] [Abstract][Full Text] [Related]
13. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Yamagishi S; Takenaka K; Inoue H Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710 [TBL] [Abstract][Full Text] [Related]
14. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Arao T; Okada Y; Mori H; Nishida K; Tanaka Y Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198 [TBL] [Abstract][Full Text] [Related]
15. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats. Younis F; Oron Y; Limor R; Stern N; Rosenthal T Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685 [TBL] [Abstract][Full Text] [Related]
17. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Ichikawa Y Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829 [TBL] [Abstract][Full Text] [Related]
18. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. Derosa G; Querci F; Franzetti I; Dario Ragonesi P; D'Angelo A; Maffioli P Hypertens Res; 2015 Oct; 38(10):690-4. PubMed ID: 25994603 [TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]